| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bone Biologics Corp$1.39
-0.09 (-6.52%)
C 55Pipeline Score MedTech · Commercial
Market Cap
2.28 M
EPS
-2.51
P/E Ratio
-0.51 $
Value Trade
10.32 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
141.60 K
Operating CF
-804.28 K
Total Assets
4.98 M
Total Liabilities
309.39 K
Equity
4.67 M
D/E Ratio
12,345
-3.94 %
Week
-12.86 %
1 Month
0 %
3 Month
-19.74 %
6 Month
-99.99 %
5 Year
-100 %
All Time
Cash Data
Cash Position
4.53 M
Monthly Burn
268.00 K
Runway
15.2 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
28.61 K
52 Week Range
1.05 - 6.75
% held by Insiders
0.04 %
% held by Institutions
0.25 %
Enterprise Value
-2.25 M
Total Shares
1.79 M
Short %
4.07 %
Float Shares
1.65 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bone Biologics Corp
2Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Drug Pipeline Intelligence
C55
Pipeline Score $35M
Pipeline ValueValuation Signal
11
Drugs Scored15.0x
rNPV / MCap Top 83%
Micro Cap (rank 156 of 911)
Percentile RankBone Biologics Corp carries a moderate pipeline score (55/100), with $7.3B risk-adjusted pipeline value, led by Risedronate in Osteoporosis (Phase 3), across $78B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Risedronate Small molecule | Osteoporosis | Phase 3 | NCT01611571 | 60% | $2.5B | COMPLETED | 31 | - | - | Nov 1, 2011 | - | Mar 4, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BBLG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BBLG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BBLG▼ -8.8%on this news
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Bone Biologics Corporation has announced a private placement of up to $9.0 million with a single institutional investor. The offering includes common stock and warrants priced at $1.42 per share. Proceeds will be used for clinical trials and corporate purposes. The closing is expected around July 9, 2026, pending customary conditions.
Read more →BBLGBone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
Bone Biologics Corporation has successfully extended the validated shelf life of its rhNELL-1 protein product to 29 months, up from 24 months. This extension is supported by third-party stability data and is expected to improve lot sizing and distribution planning as the company prepares for a pivotal study. The CEO highlighted the operational benefits and increased confidence in the product's formulation.
Read more →BBLGBone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance shee
Bone Biologics Corporation has outlined its operational, scientific, and corporate milestones achieved in 2025 and provided an outlook for 2026. Key achievements include the extension of the shelf life of its rhNELL-1 product to 24 months and completion of a $5 million public offering to support its clinical programs. The company also maintained compliance with Nasdaq's listing requirements and expanded its intellectual property portfolio. Looking forward, Bone Biologics aims to continue advancing its clinical-stage programs and strengthen its operational structure.
Read more →BBLG▼ -6.7%on this news· ran to -22% by day 3
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Bone Biologics Corporation has successfully extended the shelf life of its rhNELL-1 product to 24 months, a significant improvement from previous milestones. This extension is backed by ongoing stability data and is expected to enhance manufacturing efficiency and supply-chain flexibility. The company views this achievement as a crucial step toward commercialization and long-term shareholder value creation.
Read more →BBLG▲ +37.7%on this news
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook BURLINGTON, Mass. (
Bone Biologics Corporation (NASDAQ: BBLG) CEO Jeffrey Frelick issued a letter to stockholders detailing updates on the company's progress and outlook for their lead product, NB1. The letter highlights the anticipation of completing enrollment in a pivotal first-in-human clinical study, which is evaluating NB1's effectiveness in treating degenerative disc disease. Despite slower enrollment than expected, Frelick remains optimistic about NB1's potential to improve spinal fusion outcomes. The company also reported successful funding through a public offering and advancements in the product's shelf life.
Read more →BBLG▲ +10.1%on this news
Bone Biologics Announces Pricing of $5.0 Million Public Offering
Bone Biologics Corporation has announced the pricing of a public offering of 1,250,000 shares at $4.00 each, along with accompanying warrants. The offering is expected to raise gross proceeds of approximately $5.0 million, which the company plans to use to fund clinical trials and bolster its patent portfolio. The closing is anticipated by June 30, 2025, subject to customary conditions. Additional proceeds of up to $10.0 million may be realized if warrants are fully exercised.
Read more →BBLGBone Biologics Regains Compliance with Nasdaq Continued Listing Requirements BURLINGTON, Mass. (
Bone Biologics Corporation has announced that it has regained compliance with the Nasdaq listing requirements, following a notice indicating its previous non-compliance. The company met the minimum closing bid price requirement of $1.00 for at least 10 consecutive trading days, thereby ensuring its stock will remain listed on the Nasdaq Capital Market. Founded to focus on regenerative medicine for bone, Bone Biologics is actively developing products for spinal fusion and has rights to additional applications in trauma and osteoporosis.
Read more →BBLGBone Biologics Announces 1-for-6 Reverse Stock Split
Bone Biologics Corporation announced a 1-for-6 reverse stock split that will take effect on June 10, 2025. This decision follows stockholder approval for a reverse split within a range of 1-for-2.5 to 1-for-10. After the split, the number of shares held by shareholders will consolidate, but their percentage ownership will remain the same. The company plans to maintain its trading symbol on Nasdaq and aims to stabilize its stock price following the split.
Read more →BBLGBone Biologics Appoints Phillip T. Meikle to its Board of Directors Brings 30+ years of commercial experience in the orthopedic and spine industry BURLINGTON, Mass. (
Bone Biologics Corporation has appointed Phillip T. Meikle to its Board of Directors, effective immediately. Meikle brings over 30 years of experience in the orthopedic and spine industry, having founded and sold an orthopedic distribution company. His appointment follows the retirement of Don R. Hankey from the board, keeping the number of directors at four. The company anticipates that Meikle's extensive knowledge and industry relationships will aid in the development of their product candidate, NB1, for spinal fusion patients.
Read more →BBLGBone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds BURLINGTON, Mass. (
Bone Biologics Corporation has announced a definitive agreement for the exercise of certain existing warrants, resulting in gross proceeds of approximately $2.1 million. The company will issue new unregistered warrants alongside this, aimed at funding clinical trials and maintaining its patent portfolio. The completion of the offering is anticipated to close by August 2, 2024, contingent on customary closing conditions. These developments signal strategic moves to bolster the company's financial footing and support ongoing product development.
Read more →BBLG▼ -14.1%on this news
First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion Reminder: Management "CEO Chat" with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time BUR
Bone Biologics Corporation has treated the first two patients in a pilot clinical study evaluating its NB1 bone graft device for spine fusion. This multicenter study aims to assess the device's safety and efficacy in treating degenerative disc disease. The device combines NELL-1 protein with demineralized bone matrix to promote bone regeneration. The study has received FDA support for potential progression to pivotal trials in the U.S.
Read more →BBLGBone Biologics Announces Pricing of $2.0 Million Public Offering
Bone Biologics Corporation has priced a public offering of approximately 781,251 shares and warrants to purchase the same number of shares at $2.56 each. The gross proceeds from the offering are expected to total around $2.0 million, which the company will utilize to fund clinical trials and maintain its patent portfolio. The offering is subject to customary closing conditions and is expected to close on or about March 6, 2024. The company focuses on orthobiologic products for spine fusion, aiming to advance its development efforts with strategic partners.
Read more →BBLGBone Biologics Reports Progress with NB1 Clinical Program BURLINGTON, Mass. (
Bone Biologics Corporation announced significant progress regarding its NB1 clinical program, having received Human Research Ethics Committee approval for a multicenter pilot clinical trial. The trial will evaluate the safety and effectiveness of NB1 in 30 adult subjects undergoing spinal fusion for degenerative disc disease. The inclusion of rhNELL-1 in the product candidate is expected to support increased bone regeneration, potentially tapping into a multi-billion dollar market for spinal fusion treatments. However, the company acknowledges risks associated with developing its products that could impact outcomes.
Read more →BBLGBone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors Brings 20+ years of experience in finance and business operations at both public and private life sciences companies BURLINGTON, M
Bone Biologics Corporation has appointed Robert E. Gagnon to its Board of Directors, replacing Erick Lucera. Gagnon brings over 20 years of experience in finance and business operations from various life sciences companies, which is anticipated to benefit Bone Biologics, particularly as it prepares for its pilot study with product NB-1. His past roles include positions at Remix Therapeutics, Verastem Oncology, and Biogen Idec, among others. The company is focused on developing orthobiologic products for spine fusion markets and has additional interests in trauma and osteoporosis applications.
Read more →BBLGBone Biologics Announces 1-for-8 Reverse Stock Split
Bone Biologics Corporation announced a 1-for-8 reverse stock split effective December 20, 2023. This action was approved by stockholders on December 12 and aims to potentially improve the company's stock performance. Following the split, every eight shares will combine into one while maintaining stockholders' ownership proportions. The company is focusing on developing orthobiologic products for spine fusion markets, which were built upon preclinical research involving the Nell-1 protein.
Read more →BBLG▲ +43.6%on this news
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Bone Biologics Corporation announced a definitive agreement for a registered direct offering of 1,139,063 shares of common stock priced at $0.64 per share. Concurrently, the company will issue unregistered warrants for the same number of shares, with an exercise price of $0.52. The total expected gross proceeds from the offering are approximately $729,200, which will be used to fund clinical trials and general corporate purposes. The offering is set to close around November 20, 2023, contingent on customary conditions.
Read more →BBLGBone Biologics Prices $5.0 Million Underwritten Public Offering BURLINGTON, Mass. (
Bone Biologics Corporation has announced a public offering of 2,538,071 shares priced at $1.97 each, expecting to raise approximately $5 million. The offering is set to close on or around June 16, 2023, pending standard closing conditions. The funds raised will support the company's development of orthobiologic products for spinal fusion and other applications. The company is also granting underwriters an option to purchase additional shares.
Read more →BBLGBone Biologics CEO Issues Letter to Stockholders BURLINGTON, Mass. (
Biologics CEO Issues Letter to Stockholders Mass. (October 25, 2022) - Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Je
Read more →BBLGDRAFT #1 OCTOBER 7, 2022 Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering BURLINGTON, Mass. (
Biologics Announces Closing of $5,100,000 Underwritten Public Offering Mass. (October 12, 2022) - Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced underwritten publ
Read more →BBLGBone Biologics Prices $5,100,000 Underwritten Public Offering BURLINGTON, Mass. (
Biologics Prices $5,100,000 Underwritten Public Offering Mass. (October 7, 2022) - Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces the pricing of an underwritten public offering of 3,777,778 units of securitie
Read more →BBLGBone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix Secures rhNELL-1 Carrier for Bone Regeneration Spine Fusion Product BURLINGTON, Mass. (
Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix rhNELL-1 Carrier for Bone Regeneration Spine Fusion Product Mass. (March 7, 2022) - Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets
Read more →BBLGBone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq
Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq 18, 2021 - BURLINGTON, Mass. -Bone Biologics Corp. (NASDAQ: BBLG)("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets, today announced that it closed a pu
Read more →BBLGBone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split
Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split 13, 2021 - BURLINGTON, Mass. -Bone Biologics Corp. (NASDAQ: BBLG)("Bone Biologics" or the "Company"), a developer of orthobiologic products for spin
Read more →BBLGBone Biologics : Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation 01/07/2020 | 02:09pm EST Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for spine fusion, trauma and osteoporosis
Biologics : Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation Biologics (OTCQB: BBLG), a developer of orthobiologic products for spine fusion, trauma and osteoporosis markets, has announced that it has completed a preclinical study, which shows its rhNELL-1 g
Read more →BBLGBone Biologics Receives Human Research Ethics Committee (HREC) Approval for the First Center of a Multicenter Pilot Clinical Trial to Evaluate NB1 (NELL-1/DBX ) in Australia. BURLINGTON, MA.
Biologics Receives Human Research Ethics Committee (HREC) Approval for the First Center of a Multicenter Pilot Clinical Trial to Evaluate NB1 (NELL-1/DBX ) in Australia. MA., March 25, 2019 - Bone Biologics Corp (OTCQB: BBLG), a developer of orthobiologic products for domestic
Read more →BBLGBONE BIOLOGICS COMPLETES $500,000 OF FINANCING BURLINGTON, MA (
BIOLOGICS COMPLETES $500,000 OF FINANCING MA (March 29, 2018) - Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of $500,000 funding with Orthofix Holding, Inc. The funding re
Read more →BBLGBone Biologics adds Osteoporosis and Trauma Indications to its Portfolio BURLINGTON, MA.
adds Osteoporosis and Trauma Indications to its Portfolio MA., August 23, 2017 - Bone Biologics Corp (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it has expanded its Field of Use definition of t
Read more →BBLGBONE BIOLOGICS COMPLETES $1.4 MILLION ROUND OF FINANCING BURLINGTON, (
BIOLOGICS COMPLETES $1.4 MILLION ROUND OF FINANCING (August 22, 2017) - Bone Biologics (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of a $1.4 million funding round with Musculoskeletal Tra
Read more →BBLGBONE BIOLOGICS ANNOUNCES APPOINTMENT OF BRET HANKEY TO COMPANY'S BOARD OF DIRECTORS Burlington, MA.
BIOLOGICS ANNOUNCES APPOINTMENT OF BRET HANKEY TO COMPANY'S BOARD OF DIRECTORS MA., August 3, 2017/ - Bone Biologics Corp. (OTCQB: BBLG) announced that Bret Hankey has joined the company's board of directors. Mr. Hankey brings more than 15 years of operating and board director
Read more →BBLGBONE BIOLOGICS CORPORATION ANNOUNCES COMMENCEMENT OF A PRIVATE PLACEMENT OF SECURITIES Burlington, MA
BIOLOGICS CORPORATION ANNOUNCES COMMENCEMENT A PRIVATE PLACEMENT OF SECURITIES MA - July 24, 2017 - Bone Biologics Corporation (OTCBB: BBLG), announced today that it has commenced a private offering of up to $10,000,000 of its securities. The securities will initially only be
Read more →BBLGBone Biologics Announces Signing of Option to License Revolutionary Bone Growth Factor Nell-1 from UCLA for Use in Osteoporosis Exercise of the Option Would Expand Bone Biologics' Exclusive Rights for Nell-1 Beyond Spina
Biologics Announces Signing of Option to License Revolutionary Bone Growth Factor Nell-1 from UCLA for Use in Osteoporosis of the Option Would Expand Bone Biologics' Exclusive Rights for Nell-1 Beyond Spinal Fusion June 14, 2016 / - Bone Biologics (OTCQB: BBLG), an orthobiologi
Read more →BBLGShannon Webber O: (412) 749-9299 x5 C: (412) 608-2393 E: Shannon@AtlasStories.com BONE BIOLOGICS COMPLETES $5.75 MILLION ROUND OF FINANCING BOSTON, (
FOR IMMEDIATE RELEASE Contact: Shannon Webber O: (412) 749-9299 x5 C: (412) 608-2393 E: Shannon@AtlasStories.com BIOLOGICS COMPLETES $5.75 MILLION ROUND OF FINANCING (February 29, 2016) - Bone Biologics (OTCQB: BBLG), an orthobiologic company focused on regenerative medicine,
Read more →Competitive Position
How BBLG ranks across every disease it competes inCompetitive Position is a premium feature
See how BBLG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial